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1. Introduction 
Acute leukemia is a proliferation of immature bone marrow-derived cells (blasts) that may 
also involve peripheral blood or solid organs. The percentage of bone marrow blast cells 
required for a diagnosis of acute leukemia has traditionally been set arbitrarily at 30% or more. 
However, more recently proposed classification systems have lowered the blast cell count to 
20% for many leukemia types, and do not require any minimum blast cell percentage when 
certain morphologic and cytogenetic features are present. 
2. Acute leukemia can be classified in many ways 
(1)  by morphology and cytochemistry supplemented by immunophenotyping, as proposed 
by French-American-British (FAB) group (Bennet et al 1976) ;  (2) Proposed World Health 
Organization Classification of Acute Leukemia (Harris et al 1999); (3) by immunophenotyping 
alone, as proposed by the European Group for the  immunological classification of leukemias 
(EGIL) (Bene et al 1995 & Hayhoe FG 1988).  
The traditional classification of acute leukemia used criteria proposed by the French–
American–British Cooperative Group (FAB) , using the 30% bone marrow blast cell cutoff 
(Bennett et al, 1985). This classification system originally distinguished different leukemia 
types by morphologic features and cytochemical studies, particularly myeloperoxidase (or 
Sudan black B) and non-specific esterase staining. It was revised to include leukemia types 
that could only be accurately identified with the addition of immunophenotyping or 
electron microscopic studies (Bennett et al., 1991). Although the FAB classification failed to 
distinguish immunophenotypic groups of acute lymphoblastic leukemias, did not recognize 
the significance of myelodysplastic changes in acute myeloid leukemias or cytogenetic 
abnormalities in either leukemia type, and resulted in some subcategories of little clinical 
significance, this system provided very clear guidelines for classification. In addition, some 
distinct leukemia subtypes, particularly acute promyelocytic leukemia and acute myeloid 
leukemia with abnormal eosinophils, were found to correlate with specific cytogenetic 
aberrations and had unique clinical features, and those remain in recently proposed 
classification systems. 
Acute myelogenous leukemia (AML) was based on how leukemic blasts, the predominant 
cell in the disease process, recapitulate normal hematopoiesis. Are blasts in a given case 
myeloblasts, monoblasts, megakaryoblasts, etc., and are they un-, minimally, or moderately 
differentiated.  
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The original classification scheme proposed by the French-American-British (FAB) 
Cooperative Group  divides AML into 8 subtypes (M0 to M7) and ALL into 3 subtypes (L1 to 
L3). Although AML blasts evolve from common myeloid precursors, the 8 subtypes differ in 
degree of maturation (Table 1). As specified in the table, M0 designates AML with minimal 
morphologic or cytochemical differentiation, M1–2 AML with minimal or moderate 
granulocytic differentiation, M3 acute promyelocytic leukemia (APL), M4 AML with mixed 
myelomonocytic differentiation, M5a and M5b monoblastic leukemia with minimal or 
moderate differentiation, M6a myeloid leukemia with dysplastic background erythropoiesis, 
M6b acute erythroblastic leukemia, and M7 acute megakaryoblastic leukemia. The FAB 
classification of ALL includes 3 subtypes (L1 to L3), which are differentiated based on 
morphology, including cell size, prominence of nucleoli, and the amount and appearance of 
cytoplasm (Table 2). Approximately 75% of adult ALL cases have blasts with the B -cell 
phenotype, and 25% have blasts with the T-cell phenotype. The FAB classification of ALL and 
AML is based on morphology and cytochemical staining of blasts (Cheson et al 1990).  
 
M0 AML with no Romanowsky or cytochemical evidence of differentiation 
M1 Myeloblastic leukemia with little maturation 
M2 Myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia (APL) 
M3h APL, hypergranular variant 
M3v APL, microgranular variant 
M4 Acute myelomonocytic leukemia (AMML) 
M4eo AMML with dysplastic marrow eosinophils 
M5 Acute monoblastic leukemia (AMoL) 
M5a AMoL, poorly differentiated 
M5b AMoL, differentiated 
M6 “Erythroleukemia” 
M6a AML with erythroid dysplasia 
M6b Erythroleukemia 
M7 Acute megakaryoblastic leukemia (AMkL) 
Table 1. French-American-British (FAB) Classification of Acute Myelogenous Leukemia 
2.1 M0 Acute myeloblastic leukemia with minimally differentiated 
AML-M0 is most common in adult patients. Accounts for approximately 5-10% of all AML 
patients. WBCs show Leukocytosis in 40% and > 50% with leukocytopenia. The diagnosis is 
made if less than 3% of the blasts are positive for peroxidase or the Sudan black B reaction 
and if the Blasts are positive for the myeloid-associated markers CD13, 14, CD15 or CD33, 
CD34 and negative for B or T lineage marker (CD3, CD10, CD19 and CD5). Bone marrow 
aspirated was hypercellular in all patients and contained a large number of leukemic blasts 
(Bennette JM 1991). Almost no mature myeloid cells were seen. The blasts were small to 
medium-sized round cells with an eccentric nucleus. The nucleus often had a flattened 
shape and was sometimes lobulated or cleaved and contained fine chromatin with several 
distinct nucleoli. The cytoplasm was lightly basophilic without granules. Auer rods are not 
found. 
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Fig. 1. Acute myeloblastic leukemia AML –M0  
2.2 M1 Acute myeloblastic leukemia without maturation 
It is found in all aged groups with highest incidence seen in adult and in infants less than a 
year old. Leukocytes in about 50% of patients at the time of diagnosis was increased. The 
predominant cell in the peripheral blood is usually a poorly differentiated myeloblast with 
finely reticulated chromatin and prominent nucleoli. Auer rods are found in the blast of 50% 
of the M1. If no evidence of granules or Auer rods is present, the blasts may resemble L2 
lymphoblast. The myeloperoxidase or Sudan black B stains are positive in more than 3% of 
the blasts indicating granulocytes differentiation, the diagnosis is more likely AML-M1 than 
ALL (Bennett et al, 1976). PAS  and  alpha-naphthyl acetate esterase and naphthol AS-D-
esterase are negative. About 50% of the patients will have acquired clonal chromosome 
aberrations in the leukemic cells. CD13, 14, 15, 33 and CD34 myeloid antigens are frequently 
positive in M1 leukemia. The most common cytogenetic abnormalities are: t (9; 22) (q34; q11)  
 
 
Fig. 2. Acute myeloblastic leukemia AML-M1  
2.3 M2 Acute myeloblastic leukemia with maturation 
The presenting symptoms for M2 AML are similar to those of the M1 type. Leukocytes 
increased in 50% of patients. Myeloblast can usually be found in the blood smears and may 
be the predominant cell type. Pseudopelger–Huet and hypogranular neutrophils being most 
common cells are seen in M2. 
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The bone marrow is hypercellular and types I and II myeloblasts make up from 30-83% of 
the promyelocytes to mature segmented cells. The monocytic component is less than 20%, 
differentiating M2 from M4. Basophils in some patient (M2 baso) was increased. Eosinophils 
and their precursors may be abundant, and in some cases accounts for up to 15% of 
myelogram (Berger and Flandrin, 1984). The characteristic that distinguishes AML-M2 from 
AML-M1 is the presence of maturation at or beyond the promyelocyte stage.  Abnormal 
neutrophil maturation appears to be an integral part of AML-M2 with t(8;21) translocation. 
The neutrophils may show many abnormal nuclear segmentations and Auer rods. 
Cytochemistry; Myeloperoxidase (MPO) reaction in blast cells gives the same result as in 
AML-M1, but the reaction is often of little practical value because the granulocytic nature of 
AML-M2 is usually demonstrated clearly by the presence of maturing cells in the granulocytic 
series. Sodium fluoride does not inhibit esterase. PAS and nonspecific esterase are  negative. 
Positive reaction with CD13 and CD15 antigens are frequently seen in cases of M2. 
 
 
Fig. 3. Acute myeloblastic leukemia AML-M2 
2.4 M3 Acute promyelocytic leukemia (APL) 
The median age and survival average of APL is about 18 months and occurred in younger 
adult. M3 is of particular interest because it results in the fusion of a truncated retinoic acid 
receptor alpha (RAR-alpha) gene on chromosome 17 to a transcription unit called PML (for 
promyelocytic leukemia) on chromosome 15. It is interesting to note that high doses of the 
vitamin A derivative all-trans-retinoic acid are able to overcome thus block in differentiation 
both in vitro and in vivo and this agent has been successfully used to induce remission in 
patients.   
A "variant" form of M3 (Bennett et al, 1980) is characterized by paucity of granules within 
the promyelocytic blasts and should not be confused with monocytic leukemia.  The blasts 
are large with abundant cytoplasm, and the nucleus is usually irregular. The nucleus is often 
bilobed or markedly indented and a nucleolus can be seen in each lobe. The cytoplasm is 
completely occupied by closely packed  large granules, staining bright pink, red or purple. 
Cells containing bundles of Auer rods "faggots" randomly distributed in the cytoplasm are 
characteristic, but are not present in all cases.  
It is believed that the release of large numbers of promyelocytic granules containing a 
procoagulant initiate disseminated intravascular clotting (DIC). This is the most serious 
complication of M3 AML  occurs frequently in both AML-M3 as well as AML-M3 variant 
(McKenna et al, 1982) . Initial therapy with the differentiating agent all-trans-retinoic acid 
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(ATRA) has improved significantly the treatment of AML-M3 in this regard; early mortality 
as a result of DIC is substantially reduced.   
Cytochemistry: Peroxidase  (MPO) and Sudan black B are strong positive. The periodic acid 
Schiff (PAS) is negative and Nonspecific esterase is also weak positive . The MPO reaction is 
also strong positive in the AML-M3 variant.  
Immunological studies demonstrate positivity with CD13, CD15, CD1 and CD33 myeloid 
antigens. Cytogenetic studies have revealed a high prevalence (almost 50%) of the 
chromosomal translocation t(15; 17) associated with both AML M3 and M3 variant . M3 
AML with t(15;17) is usually characterized by the association of the lymphoid marker, CD2 
and CD19, with myeloid markers and the negativity of HLA-DR and CD34.  
 
 
Fig. 4. Promyelocytic leukemia AML-M3 
 
 
Fig. 5. Acute myelomonocytic leukemia M4 
2.5 M4 Acute myelomonocytic leukemia (AMML) 
It is distinguished from M1, M2, and M3 by an increased proportion of leukemia monocytic 
cells in the bone marrow or blood or both. Gingival hyperplasia with gingival bleeding is 
present. Serum and urine levels of muramidase (lysozyme) are usually elevated because of 
the monocytic proliferation. The leukocyte count is usually increased monocytic cells 
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(monoblast, promoncytes, monocytes), are increased to 5000/L or more. Anemia and 
thrombocytopenia are present in almost all cases. The marrow differs from M1, M2 and M3 
in those monocytic cells exceed 20% of the nonerythroid nucleated cells. The sum of the 
myelocytic cells including myeloblasts, promyelocytes and later granulocytes is >20% and 
<80% of nonerythroid cells. This bone marrow picture together with a peripheral blood 
monocyte count of 5000/L or more is compatible with a diagnosis of M4. 
Confirmation of the monocytic component of this subgroup requires cytochemistry. The 
profile includes positive reactions for sudan black B or peroxidase and both specific and 
non-specific esterase. A few cases of M4 AML are characterized by increased marrow 
eosinophils and classified as M4e (Berger et al 1985) . Immunological studies demonstrate 
positivity with CD13, CD33, CD11b and CD14. Cytogenetic: inv(16) (p13; q22) and del 
(16)(q22) . 
2.6 M5 Acute monoblastic leukemia (AMoL)   
Common findings are weakness, bleeding and a diffuse erythematous skin rash. There is a 
high frequency of extramedulary infiltration of the lungs, colon, meninges, lymphnodes, 
bladder and larynx and gingival hyperplasia. Serum and urinary muramidase levels are 
often extremely high. The one criterion for a diagnosis of M5 is that 80% or more of all 
nonerythroid cells in the bone marrow are monocytic cells. There are two distinct forms 5a 
(maturation index <4%) and 5b   (maturation index > 4%).M5a: Granulocyte <20% and 
Monocyte >80%   >80% monoblast. M5b: Granulocyte <20% and Monocyte >80%   <80% 
monoblast (Characterized by the presence of all developmental stages of monocytes; 
monoblast, promonocyte, monocyte) 
Cytochemistry: Non-specific esterase stains and alpha-naphthyl esterase are positive and 
PAS is negative. Myeloperoxidase and Sudan black are weak diffuse activity in the 
monoblast. The use of alph-naphthyl butyrate esterase (ANBE) is advantageous because of 
its greater degree of specificity and stronger reaction, and also because sodium fluoride 
inhibition is not required (Shibata et al, 1985). Immunological studies demonstrate positivity 
with CD11b and CD14. There is a strong association between AML M5/M4 and deletion 
and translocations involving band 11q23.   
 
 
Fig. 6. M5 Acute monoblastic leukemia (AMoL) 
www.intechopen.com
 
Classification of Acute Leukemia 
 
9 
2.7 M6 “Erythroleukemia"   
M6 is a rare form of leukemia that primarily affects the peripheral cells. It is nonsexist in 
children. The clinical manifestations are similar to other types of AML. The most frequent 
presentation is bleeding. The most dominant changes in the peripheral blood are anemia 
with sticking poikilocytosis and anisocytosis. Nucleated red cells demonstrate abnormal 
nuclear configuration. The leukocytes and platelets are usually decreased. The diagnosis of 
erythroleukemia can be made when more than 50% of all nucleated bone marrow cells are 
erythroid and 30% or more of all remaining nonerythroid cells are type I or type II blast cells 
(Bennett et al, 1985). The erythroblast is abnormal with bizarre morphologic features. Giant 
multilobular or multinucleated forms are common. Other features are; fragmentation, 
Howell-Jolly bodies, ring sideroblast, megaloblastic and dyserythropoiesis changes are 
common. The cytochemistry of erythroblasts are normally PAS negative but in AML-M6, 
erythroblasts especially pronormoblast demonstrates coarse positivity of PAS. Blast cells 
express a variety of myeloid associated antigens such as CD13, CD33, anti-MPO with or 
without expression of precursor-cell markers as CD34, HLA-Dr determinants as for blast 
cells from other AML subtypes. In M6-variant forms, the more differentiated cells can be 
detected by the expression of glycophorin A and the absence of myeloid markers. 
 
 
Fig. 7. M6 “Erythroleukemia” 
2.8 M7 Acute megakaryoblastic leukemia (AMkL) 
M7 is rare. It occurs as a leukemia transformation of chronic granulocytic leukemia (CGL) 
and myelodysplastic syndrome (MDS). Pancytopenia is characteristic at initial diagnosis. 
Peripheral blood shows micromegakaryocytes and undifferentiated blasts. Bone marrow 
dry tap is common. Bone marrow biopsy show increased fibroblasts and/or increased 
reticulin and presence of greater than 30% blast cells. The diagnosis of M7 should be 
suspected when the blast cells show cytoplasmic protrusion or budding. As bone marrow 
smears obtained by aspiration may not be adequate to make a diagnosis, the peripheral 
blood films must be examined carefully for the presence of micromegakaryoblasts. Bone 
marrow biopsy sections are usually necessary and show a prominent reticulin fibrosis and 
excessive numbers of small blasts.  
Cytochemistry: Peroxidase is negative, PAS +/-, Esterase +/- and positive acid phospatase. 
Cytochemical positivity for -naphthyl acetate esterase reaction and negative reaction with 
-naphthyl butyrate esterase is unique to megakaryoblast. (Monocytes react positively with 
both esterase substrates).  
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The monoclonal antibodies that reacts with platelet glycoprotein Ib, IIb/IIIa and IIIb, using 
immunologic technique as well as CD41, CD42 and CD61 positivity. 
There is no unique chromosomal abnormality associated with acute megakaryoblastic 
leukemia, with the exception of t(1;22)(p13;q13), which has been found almost exclusively in 
young children, less than 18 months old who do not have Downís syndrome. 
 
 
Fig. 8. M7 Acute megakaryoblastic leukemia (AMkL) 
 
Morphologic Classification 
FAB Type Features of Blasts 
L1 Small cells with scant cytoplasm; nucleoli indistinct and not visible 
L2 Large, heterogeneous cells with moderately abundant cytoplasm; 
clefting and indentation of nucleus; large and prominent nucleoli 
L3 Large cells with moderately abundant cytoplasm; regular, oval-to-round 
nucleus; prominent nucleoli; 
prominent cytoplasmic basophilia and cytoplasmic vacuoles 
Table 2. Morphologic Classification of Acute Lymphocytic Leukemia 
Acute lymphoblastic leukemia (ALL)  is divided in FAB L1 (children), L2 (older children 
and adult), and L3 (patients with leukemia secondary to Burkitt's lymphoma. These types 
are defined according to two criteria (1) the occurrence of individual cytologic features and 
(2) the degree of heterogeneity among the leukemic cells. These features considered are cell 
size, chromatin, nuclear shape, nucleoli, and degree of basophilia in the cytoplasm and the 
presence of cytoplasmic vacuolation (Bennett et al 1976). 
ALL-L1: Homogenous cells  (Small cell): One population of cells within the case. Small cells 
predominant, nuclear shape is regular with occasional cleft. Nuclear contents are rarely 
visible. Cytoplasm is moderately basophilic. L1 accounts 70% of patients. The L1 type is the 
acute leukemia that is common in childhood, with 74% of these cases occurring in children 
15 years of age or younger.  
ALL-L2: Heterogeneous cells: Large cells with an irregular nuclear shape, cleft in the 
nucleus are common. One or more large nucleoli are visible. Cytoplasm varies in colour and 
nuclear membrane irregularities. L2 accounts 27% of ALL patients. The FAB-L2 blast may be 
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confused with the blasts of acute myeloid leukemia. Approximately 66% of these cases of 
ALL in patients older than 15 years are of type 2. 
 
 
Fig. 9. Acute lymphoblastic leukemia L1 
 
 
Fig. 10. Acute lymphoblastic leukemia L2 
ALL-L3: Burkitt's lymphoma type: Cells are large and homogenous in size, nuclear shape is 
round or oval. One to three prominent nucleoli and sometimes to 5 nuleoli are visible. 
Cytoplasm is deeply basophilic with vacuoles often prominent. Intense cytoplasmic 
basophilia is present in every cell, with prominent vacuolation in most.  A high mitotic 
index is characteristic with presence of varying degrees of macrophage activity. Mature B-
lymphoid markers are expressed by most cases.  
 
 
Fig. 11. Acute lymphoblastic leukemia L3 
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Acute Myeloid Leukemia (AML) and Related Precursor Neoplasm 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Acute promyelocytic leukemia with t(15;17)(q22;q12); PML-RARA 
AML with t(9 ;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML with mutated NPM1 
AML with mutated CEBPA 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Myeloid sarcoma  
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid denderitic cell neoplasm 
Table 3. World Health Organization Classification of Acute Myelogenous Leukemia (2008) 
AML defined as ≥20% blasts in blood or bone marrow; however, clonal, recurring 
cytogenetic abnormalities should be considered AML regardless of blast percentage. 
Ongoing clinical trials may continue to use French-American-British (FAB) criteria of ≥30% 
blasts until completion of trial. FAB classification identified as M0 through M7. 
The classification schemes by the World Health Organization (WHO) require the additional 
evaluation of the leukemic blasts by molecular analysis and flow cytometry (Harris NL 1997 
& Brunangelo Falini 2010, Sachdeva et al 2006). The results of these 4 methods of evaluation 
(i.e, morphology, staining, molecular analysis, flow cytometry) not only differentiate ALL 
from AML, but also categorize the subtypes of acute leukemia. Table 3 summarizes the new 
classification of AML as proposed by WHO, Knowing the subtype of a patient’s leukemia 
helps in predicting the clinical behavior of the disease and the prognosis, and in making 
treatment recommendations. This classification also improves the reproducibility of 
diagnoses and stresses the heterogeneity of the subtypes of AML and ALL (Vardiman 2009). 
Recent advances in molecular biology have shown that various subtypes of AML and ALL 
behave differently and should not be treated similarly. For example, the identification of M3 
AML (acute promyelocytic leukemia) is crucial because it is associated with disseminated 
intravascular coagulation (DIC), and retinoic acid, in addition to chemotherapy, is the 
treatment of choice.  
The two most significant differences between the FAB and the WHO classifications are: 
(a) A lower blast threshold for the diagnosis of AML: The WHO defines AML when the 
blast percentage reaches 20% in the bone marrow. 
(b) Patients with recurring clonal cytogenetic abnormalities should be considered to have 
AML regardless of the blast percentage (8;21)(q22;q22), t(16;16)(p13;q22), inv(16)(p13;q22), 
or t(15;17)(q22;q12) (Arber DA  et al 2008abc, Weinberg OK et al 2009). 
The world Health Organization (WHO) classification has changed the grouping of ALL to 
reflect increased understanding of the biology and molecular pathogenesis of the diseases. In 
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addition to discarding the L1-L3 terms, the new classification characterizes these heterogenous 
diseases based upon immunophenotype into 3 basic categories: precursor B-cell ALL, 
precursor T-cell ALL, and mature B-cell ALL (Burkitt lymphoma/leukemia) (Jaffe et al 2001) 
 
WHO classification 
Precursor B-cell ALL/LBL 
Cytogenetic subgroups 
  t(9;22)(q34,q11),BCR/ABL 
  t(v;11q23);MLL rearranged 
  t(1;19)(q23;p13);PBX1/E2A 
  t(12;21)(p13;q22);TEL/AML1 
  Hypodiploid 
  Hyperdiploid, >50 
 
Precursor T-cell ALL/LBL 
 
Mature B-cell leukemia/lymphoma 
ALL= acute lymphoblastic leukemia;  
LBL= lymphoblastic lymphoma;  
MLL= mixed lineage leukemia  
Table 4. World Health Organization classification of acute lymphoblastic leukemia 
Abnormalities in chromosome number as well as structural rearrangements (translocations) 
occur commonly in ALL. Important cytogenetic abnormalities in precursor B-cell ALL that 
are associated with a poor prognosis include t(9;22) or Philadelphia chromosome-positive 
(Ph+) ALL, which increases in frequency with age; t(4;11); hypodiploidy, especially if <45% 
chromosomes ; and trisomy 8 in adult ALL. The t(4;11) results from a balanced translocation 
involving a gene on the long arm of chromosome 11 at band q23 (11q23), known as the 
mixed lineage leukemia (MLL) gene. MLL gene translocations occur most commonly in 
infancy and are associated with both acute lymphoid and myeloid leukemias. 
3. European Group for the Immunological classification of Leukemias (EGIL) 
The European Group for the Immunological Classification of Leukemias (EGIL)(Bene MC et al 
1995 & Hoelzer et al 2002)) has proposed that acute leukaemia be classified on the basis of 
immunophenotype alone. This classification has the strength that it suggests standardized 
criteria for defining a leukaemia as myeloid, T lineage, B lineage, or biphenotypic. It also 
suggests criteria for distinguishing biphenotypic leukaemia from AML with aberrant 
expression of lymphoid antigens, and from ALL with aberrant expression of myeloid antigens. 
However, a purely immunological classification has the disadvantage that discrete entities 
may fall into one of two categories; for example some cases of AML of FAB M2 subtype 
associated with t(8;21)(q22;q22) would be classified as "AML of myelomonocytic lineage", 
while others would be classified as "AML with lymphoid antigen expression," depending on 
whether or not a case showed aberrant expression of CD19. In addition, rare cases of acute 
leukaemia have been described which were clearly myeloid when assessed by cytology and 
cytochemistry but which did not express any of the commonly investigated myeloid antigens. 
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Precursor B-lymphoblastic leukemia ( HLA-DR+, TdT+, CD19+, and/or CD79a+, 
and/or CD22+, and/or CD34+). This type of ALL accounts for around 75% of 
adult cases and is subdivided into the following groups: 
a.  Pro B-ALL expresses HLA-DR, TdT, and CD19. CD10-, cytoplasmic 
immunoglobulin negative; represents approximately 10% of adult ALL. 
b. Common ALL is characterized by the presence of CD10, cytoplasmic 
immunoglobulin negative; comprises greater than 50% of adult cases of ALL. 
c.  Pre B-ALL is characterised by the expression of cytoplasmic immunoglobulin 
and CD10; this subtype of ALL is identified in nearly 10% of adult cases. 
d. Mature B-ALL is found in approximately 4% of adult ALL patients. The blast 
cells express surface antigens of mature B cells, including surface membrane 
immunoglobulin (SmIg+). They are typically TdT and CD34 negative and have 
L3 morphology. This category overlaps with Burkitt lymphoma, which is 
included under the mature B-cell neoplasms. 
Precursor T-lymphoblastic leukemia 
Cells are TdT+ in addition to cytoplasmic CD3+ and CD34+. This type of ALL 
accounts for around 25% of adult cases and is subdivided into: 
a. Pro T-ALL CD2-, CD7+, CD4-, CD8- seen in around 7% of adult ALL. 
b. Pre T-ALL CD2+, CD7+, CD4-, CD8-. 
c. Cortical T-ALL or Thymic ALL (Thy ALL) is CD1a+ and accounts for 17% of 
adult ALL CD7+, CD2+, CD5+, CD4+, CD8+ 
d. Mature T-ALL are surface CD3+, CD2+, CD7+, CD4 or 8, and 
TdT/CD34/CD1a- and make up approximately 1% of adult ALL. 
Table 5. European Group for the Immunological Characterization of Leukemias (EGIL) 
classification of acute lymphocytic leukemia (Hoelzer  2002) 
The consensus considers a 20% minimum threshold to define a positive reaction of blast 
cells to a given monoclonal antibody. Roughly 75% of cases of adult ALL are of B-cell 
lineage. B-lineage markers are CD19, CD20, CD22, CD24, and CD79a (Huh 2000).  
The earliest B-lineage markers are CD19, CD22 (membrane and cytoplasm) and CD79a 
(Campana 1988). A positive reaction for any two of these three markers, without further 
differentiation markers, identifies pro-B ALL. The presence of CD10 antigen (CALLA) 
defines the "common" ALL subgroup. Cases with additional identification of cytoplasmatic 
IgM constitute the pre-B group, whereas the presence of surface immunglobulin light chains 
defines mature B-ALL. 
T-cell ALL constitutes approximately 25% of all adult cases of ALL. T-cell markers are CD1a, 
CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7 and CD8. CD2, CD5 and CD7 
antigens are the most immature T-cell markers, but none of them is absolutely lineage-
specific, so that the unequivocal diagnosis of T-ALL rests on the demonstration of 
surface/cytoplasmic CD3.  
ALL of B or T lineage can additionally express myeloid antigens or stem-cell antigen CD34. 
The latter has little diagnostic relevance but can be prognostically important (De Waele 2001) 
The scoring system recently proposed by the EGIL group addressed the characterization of the 
acute leukemia as B or T lineage ALL, or AML by including the most specific markers for the 
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lymphoid and myeloid lineages among those of earlier stages of cell differentiation, plus some 
non-specific but stem-cell markers. The system introduced a modified terminology specific to 
each 'maturation' step within the B- or T-cell lineage (EGIL 1995) and was confirmed as 
adequate for both diagnosis and subclassification of ALL (Thalhammer-Scherrer 2002). 
4. European Group for the Immunological characterization of Leukemias 
(EGIL) classification for biphenotypic acute leukemia 
Biphenotypic acute leukemia (BAL), or acute leukemia with a single population of blasts 
coexpressing markers of two different lineages, is a rare clinical entity.  
The scoring systems proposed by Catovsky et al. and by the EGIL (Bene 1995) allowed for a 
better definition of biphenotypic acute leukemia (BAL), clearly distinguishing them from 
classical AL expressing aberrantly one or two markers of another lineage. However, 
increasing evidence suggests that this system has limitations, as acknowledged by the 2008 
World Health Organization (WHO) Classification of Tumors of Hematopoietic and 
Lymphoid Tissues. Although substantially improved in relation to the EGIL, the new WHO 
Classification is still not optimal for guiding the clinical management of patients with BAL. 
Typical examples of such aberrations are the expression of CD15 on B-ALL(Maynadie et al 
1997),  or of CD2 on acute promyelocytic –AML( Albano 2006). In 1998, the EGIL further 
refined this scoring system by attributing one point for the expression of CD117, after 
showing the strong relationship of this marker with engagement in the myeloid lineage 
(Bene MC et al 1998) . To identify BAL, it is therefore necessary to consider aberrant co-
expression of markers usually associated to different lineages, with a score higher than 2 in 
more than one lineage (Zhao XF et al 2009) 
 
Myeloid lineage T-lineage B-lineage  
MPO CD3 CD79 2 point 
Lisozyme Anti TCR IgM 
  CD22 
CD13 CD2 CD19 1 point 
CD33 CD5 CD10 
CD65 CD8 CD20 
CD10 
CD14 TdT TdT 0.5 point 
CD15 CD17 CD24 
CD64, CD117 CD10 
Table 6. EGIL Scoring system for biphenotypic acute leukemia 
Biphenotypic acute leukemia is defined when scores are >2 for the myeloid lineage and >1 
for the lymphoid lineage. In some T-ALL cases, clonality of TCR alphabeta rearrangements 
can now be assessed cytoflourmetrically (Langerak 2001, Xu XQ et al 2009).  
The prognosis of biphenotypic acute leukemia patients is poor when compared with de 
novo acute myeloid leukemia or acute lymphoblastic leukemia. Biphenotypic acute 
leukemia patients showed a much higher incidence of CD34 antigen expression, complex 
abnormal karyotype, extramedullary infiltration, relapse, and resistance to therapy after 
relapse (Xu XQ et al 2009). 
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5. Conclusion  
Acute leukaemia can be classified in many ways. An ideal classification is one which 
recognizes real entities with fundamental biological differences. The FAB classification of 
ALL and AML is based on morphology and cytochemical staining of blasts. However, the 
recent classification schemes proposed by the World Health Organization (WHO) require 
the additional evaluation of the leukemic blasts by molecular analysis and flow cytometry. 
The results of these 4 methods of evaluation (ie, morphology, staining, molecular analysis, 
flow cytometry) not only differentiate ALL from AML, but also categorize the subtypes of 
acute leukemia . Recent advances in molecular biology have shown that various subtypes of 
AML and ALL behave differently and should not be treated similarly. For example, the 
identification of M3 AML (acute promyelocytic leukemia) is crucial because it is associated 
with disseminated intravascular coagulation (DIC), and retinoic acid, in addition to 
chemotherapy, is the treatment of choice.  
The European Group for the Immunological Classification of Leukemias (EGIL) has 
proposed that acute leukaemia be classified on the basis of immunophenotype alone. This 
classification has the strength that it suggests standardized criteria for defining a leukaemia 
as myeloid, T lineage, B lineage, or biphenotypic. It also suggests criteria for distinguishing 
biphenotypic leukaemia from AML with aberrant expression of lymphoid antigens, and 
from ALL with aberrant expression of myeloid antigens. 
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